Summary Slide.png (103.97 kB)
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
figure
posted on 2021-03-22, 10:25 authored by Adis journals on behalf of, Xiaohui Zeng, Qiao Liu, Liubao Peng, Ye Peng, Lidan Yi, Xia Luo, Sini Li, Xiaomin Wan, Chongqing TanArticle full text
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
